🔎 Trials Near Me

Home › High Blood Pressure › NCT07511361

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

RecruitingPhase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Key Inclusion Criteria:

* Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg/m2
* Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization
* At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg
* Presence of established cardiovascular or renal disease

Key Exclusion Criteria:

* Has known history of secondary hypertension
* Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)
* Has abnormal thyroid function with clinical significance
* Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening
* History of and/or obvious clinical signs or symptoms of cirrhosis or other significant liver disease
* Alanine aminotransferase or aspartate aminotransferase \>2 x upper limit of normal
* Most recent hospitalization was for non-cardiovascular or non-renal conditions

About the study

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.

What is being tested

Sponsor: Kardigan, Inc. · Participants: 140 · Started: Jun 23, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07511361

Locations in the U.S.

ColoradoWestern Nephrology and Metabolic Bone Disease, PC - Arvada, Arvada
FloridaHomestead Associates in Research, Homestead
Progressive Medical Research, Port Orange
IllinoisEagle Clinical Research, Chicago
MichiganHenry Ford Hospital, Detroit
New YorkRichmond University Medical Center (RUMC), Staten Island
OhioResearch Innovations, LLC, Beavercreek
Cleveland Clinic, Cleveland (Not yet recruiting)
South CarolinaOnSite Clinical Solutions, LLC, Fort Mill
TennesseeChattanooga Research & Medicine CHARM, Chattanooga
TexasLaguna Clinical Research Associates, Laredo
Tapia Internal Medicine Clinic, Paris
Baylor Scott and White Research Institute - Temple, Temple

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.